Lundbeck enters migraine race with $2B takeout of Alder

Lundbeck will add a CGRP inhibitor to its neurology pipeline by buying Alder for just shy of $2 billion, but the Scandinavian pharma will be playing catch-up as eptinezumab will likely be fourth among drugs in its class.

On Monday the

Read the full 403 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE